Supplemental table 2.
Colorectal cancer is considered to have few comorbidities in patients who are taking certain pharmaceuticals for diabetes, hypertension, hyperlipidemia, and depression
Depression |
Hypertension |
Diabetes |
Hyperlipidemia |
Etc. |
Amitriptyline |
Alacepril |
Imidapril |
Acarbose |
Cholestyramine |
Dichloroacetate |
Amoxapine |
Amiloridee |
Indapamide |
Chlorpropamide |
Ezetimibe |
Fibrate |
Bupropion |
Amineptine |
Indapamide |
Chlorpropamide |
Fibrate |
Somatostatin |
Citalopram |
Amlodipine |
Irbesartan |
Glibenclamide |
Lipitor |
|
Clomipramine |
Arotinolol |
Isradipine |
Gliclazide |
Nicotinic acid |
|
Dothiepin |
Atenolol |
Labetalol |
Glimepiride |
Omega-3 fatty acid |
|
Escitalopram |
Barnidipine |
Lacidipine |
Glimepiride |
Ramipril |
|
Fluoxetine |
Benazepril |
Lercanidipine |
Glipizide |
|
|
Fluvoxamine |
Benidipine |
Lisinopril |
Glipizide |
|
|
Imipramine |
Betaxolol |
Losartan |
Gliquidone |
|
|
Maprotiline |
Bevantalol |
Manidipine |
Insulin Lispro |
|
|
Medifoxamine |
Bisoprolol |
Metoprolol |
Miglitol |
|
|
Mianserine |
BunazosinW |
Moexipril |
Nateglinide |
|
|
Milnacipran |
Candesartan |
Nadolol |
Pioglitazone |
|
|
Mirtazapine |
Captopril |
Nicardipine |
Repaglinide |
|
|
Moclobemide |
Carteolol |
Nifedipine |
Rosiglitazone |
|
|
Nefazodone |
Carvedilol |
Perindopril |
Voglibose |
|
|
Paroxetine |
Celiprolol |
Prazosin |
|
|
|
Quinupramine |
Chlorthalidon |
Propranolol |
|
|
|
Sertraline |
Cilazapril |
Quinapril |
|
|
|
Tianeptine |
Cilnidipine |
Rosiglitazone |
|
|
|
Toloxatone |
Delapril |
Spironolactone |
|
|
|
Venlafaxine |
Diltiazem |
Telmisartan |
|
|
|
|
Doxazosin |
Temicapril |
|
|
|
|
Doxepin |
Terazosin |
|
|
|
|
Efonidipine |
Torasemide |
|
|
|
|
Enalapril |
Trazodone |
|
|
|
|
Eprosartan |
Tripamide |
|
|
|
|
Felodipine |
Valsartan |
|
|
|
|
Fosinopril |
Verapamil |
|
|
|
Figure 1The proportion of medical/non-medical expenses by gender (unit: 1 000 000 Korean won). (A) Female and (B) male.
Table 1.Treated prevalence of CRC in 2010
|
Characteristics
|
Period prevalence of CRC
|
Age (y) |
Total male population1
|
Total female population2
|
No. of men with CRC3
|
No of women with CRC4
|
Male |
Female |
Total |
25 310 385 |
25 205 281 |
49 535 |
34 059 |
195.710 |
135.13 |
0-9 |
2 463 577 |
2 293 947 |
- |
2 |
- |
0.09 |
10-19 |
3 598 726 |
3 228 149 |
20 |
11 |
0.56 |
0.34 |
20-29 |
3 565 624 |
3 301 332 |
148 |
123 |
4.15 |
3.73 |
30-39 |
4 272 740 |
4 097 809 |
1038 |
868 |
24.29 |
21.18 |
40-49 |
4 513 652 |
4 330 700 |
4260 |
3292 |
94.38 |
76.02 |
50-59 |
3 543 441 |
3 523 382 |
11 356 |
7362 |
320.48 |
208.95 |
60-69 |
1 999 523 |
2 191 806 |
16 460 |
9610 |
823.20 |
438.45 |
70-79 |
1 070 720 |
1 547 805 |
13 271 |
9226 |
1239.45 |
596.07 |
80-89 |
253 899 |
597 869 |
2791 |
3297 |
1099.26 |
551.46 |
90-100 |
28 483 |
92 482 |
191 |
268 |
670.58 |
289.79 |
Table 2.Economic burden of colorectal cancer in Korea, 2010
Service |
Days of care |
Direct costs (①)1
|
Inirect costs (②)2
|
Total costs (①+②)
|
Direct medical care costs
|
Direct non-medical care costs
|
|
|
|
Paid by insurer (1) |
Paid by patients (2) |
Non covered (3) |
Prescribed pharmaceuticals (4) |
Sub total (1)+(2)+(3)+(4) |
Trans-portation (5) |
Guardian’s costs (6) |
Lost productivity (7) |
Cost of premature death (8) |
|
Out |
874 408 |
211 840 |
14 192 |
47 450 |
33 748 |
307 231 |
559 056 |
20 302 |
24 635 |
(male) 755 318 |
|
In |
1 508 545 |
341 528 |
23 269 |
102 592 |
|
467 388 |
503 310 |
105 078 |
107 713 |
(female) 271 993 |
|
Total |
2 382 953 |
553 368 |
37 461 |
150 042 |
33 748 |
774 618 |
1 062 366 |
125 381 |
132 348 |
1 027 311 |
3 122 023 |
Table 3.Medical/non-medical care expenses by gender
Age (y) |
Male
|
Female
|
Total cost |
Per capita cost |
Direct medical care cost |
Direct non- medical care cost |
Lost productivity |
Cost of premature death |
Total cost |
Per capita cost |
Direct medical care cost |
Direct non- medical care cost |
Lost productivity |
Cost of premature death |
0-9 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
10-19 |
1713 |
86 |
301 |
485 |
0 |
927 |
360 |
33 |
173 |
19 |
0 |
168 |
20-29 |
11 555 |
78 |
1727 |
2707 |
356 |
6764 |
7218 |
59 |
1821 |
240 |
254 |
4902 |
30-39 |
69 927 |
67 |
9868 |
16 111 |
3005 |
40 943 |
50 180 |
58 |
11411 |
15 238 |
4341 |
19 191 |
40-49 |
286 817 |
67 |
38 990 |
68 096 |
16 242 |
163 489 |
168 160 |
51 |
42 088 |
54 750 |
6623 |
64 698 |
50-59 |
616 287 |
54 |
101 000 |
174 845 |
36 365 |
304 077 |
320 271 |
44 |
83 717 |
111 869 |
23 097 |
101 588 |
60-69 |
633 057 |
38 |
129 893 |
232 741 |
31 304 |
239 118 |
327 191 |
34 |
99 846 |
135 140 |
10 759 |
81 445 |
70-79 |
265 987 |
20 |
94 159 |
171 828 |
0 |
0 |
220 356 |
24 |
99 576 |
120 779 |
0 |
0 |
80-89 |
50 514 |
18 |
17 371 |
33 143 |
0 |
0 |
82 472 |
25 |
38 473 |
43 999 |
0 |
0 |
90-100 |
3053 |
16 |
1066 |
1987 |
0 |
0 |
6906 |
26 |
3138 |
3768 |
0 |
0 |
Total |
1 938 908 |
39 |
394 375 |
701 943 |
87 273 |
755 318 |
1 183 115 |
35 |
380 244 |
485 804 |
45 074 |
271 993 |